DAREONᵀᴹ-8 Study is for adults with a type of lung cancer called **extensive stage small cell lung cancer (ES-SCLC)**. The study tests how well people handle doses of a new drug, BI 764532, when combined with **standard of care (SoC)** treatments like chemotherapy and immunotherapy. BI 764532 is an antibody-like molecule, which means it might help your immune system fight cancer. The drug and SoC treatments are given through a needle into a vein.
The goal is to find the highest dose of BI 764532 that people can handle without too many side effects. If participants feel better and can tolerate the treatment, they will continue with it for the study's duration. Participants will regularly visit the study site, where doctors will check their health, run lab tests, and watch for any problems caused by the treatment.
- The study is only for people who have not had systemic treatment for ES-SCLC before.
- Participants need to visit the study site regularly for health checks.
- The study is open only to adults over 18 years old.